Sanofi's AERIFY-1 Met Primary Endpoint, AERIFY-2 Did Not

May 30 (Reuters) - Sanofi SA SASY.PA:

• PRESS RELEASE: ITEPEKIMAB MET THE PRIMARY ENDPOINT IN ONE OF TWO COPD PHASE 3 STUDIES

• SANOFI SA - AERIFY-1 STUDY SHOWS SIGNIFICANT REDUCTION IN COPD EXACERBATIONS

• SANOFI - ITEPEKIMAB WAS GENERALLY WELL TOLERATED IN BOTH AERIFY-1 AND AERIFY-2

• SANOFI SA - AERIFY-2 STUDY DOES NOT MEET PRIMARY ENDPOINT

• SANOFI SA - ITEPEKIMAB GENERALLY WELL TOLERATED IN BOTH STUDIES

• SANOFI - SANOFI AND REGENERON ARE ASSESSING DATA AND WILL DISCUSS WITH REGULATORY AUTHORITIES TO EVALUATE NEXT STEPS